Table 2.
Meta-analysis of the association between rs5498 and DR in type 2 diabetes
| Evaluation | Number of studies | OR (95% CI) | P | P for heterogeneity | I2 (%) |
|---|---|---|---|---|---|
| GA + GG versus AA | |||||
| Total | 9 | 1.00 (0.66–1.50) | 0.987 | < 0.001 | 84.0 |
| Asians | 8 | 0.96 (0.61–1.50) | 0.843 | < 0.001 | 85.2 |
| Caucasians | 1 | 1.40 (0.86–2.27) | 0.173 | NA | NA |
| PDR | 4 | 1.22 (0.61–2.47) | 0.577 | < 0.001 | 86.8 |
| NPDR | 3 | 0.60 (0.29–1.21) | 0.151 | 0.007 | 80.0 |
| GG versus GA + AA | |||||
| Total | 9 | 1.24 (0.86–1.77) | 0.245 | 0.003 | 65.3 |
| Asians | 8 | 1.15 (0.79–1.68) | 0.469 | 0.008 | 63.2 |
| Caucasians | 1 | 2.00 (1.15–3.48) | 0.014 | NA | NA |
| PDR | 4 | 1.90 (0.80–4.50) | 0.146 | < 0.001 | 84.2 |
| NPDR | 3 | 0.92 (0.58–1.47) | 0.724 | 0.477 | 0.0 |
| GG versus AA | |||||
| Total | 9 | 1.14 (0.68–1.92) | 0.611 | < 0.001 | 78.5 |
| Asians | 8 | 1.04 (0.60–1.81) | 0.887 | < 0.001 | 78.1 |
| Caucasians | 1 | 2.21 (1.16–4.22) | 0.016 | NA | NA |
| PDR | 4 | 1.91 (0.64–5.73) | 0.246 | < 0.001 | 87.6 |
| NPDR | 3 | 0.77 (0.47–1.25) | 0.286 | 0.171 | 43.5 |
| G allele versus A allele | |||||
| Total | 9 | 1.08 (0.81–1.45) | 0.592 | < 0.001 | 85.7 |
| Asians | 8 | 1.05 (0.76–1.44) | 0.790 | < 0.001 | 86.3 |
| Caucasians | 1 | 1.44 (1.06–1.95) | 0.021 | NA | NA |
| PDR | 4 | 1.34 (0.71–2.52) | 0.364 | < 0.001 | 82.5 |
| NPDR | 3 | 0.71 (0.43–1.17) | 0.180 | 0.011 | 77.9 |
CI confidence interval, DR diabetic retinopathy, NA not applicable, NPDR non-proliferative diabetic retinopathy, OR odds ratio, PDR proliferative diabetic retinopathy